Life Sciences

Sept 28th 11a PT/ 2p ET

Join us for a web panel discussion on how to successfully move a life science organization from founding to exit. During this discussion, founders will provide guidance on how executive teams can partner business and science together to overcome the stumbling blocks along the way and achieve results. 

Sept 21st 8a PT/ 11a ET

GDP is the responsibility of everyone that contributes (i.e. via submission or creation) clinical trial documentation to the TMF.

This webinar will evaluate the regulations that support GDP, best practices on how document contributors can apply the golden rule of research to their TMF and how to avoid writing too many and unnecessary Note-to-Files (NTFs).

This infographic offers insight on the strategic oncology alliances made during Q1-Q2 of 2017 by geographic region, development phase and molecule type. Get a high level view of the alliance types by development stage: co-development, co-marketing, joint venture or licensing agreements. Understand the number of deals within a given oncology-related indication. And get a world-view of the global oncology dealmaking space, with deal information by country. 

With a busy 2017, we've compiled the biopharma partnering and M&A deal activity so far this year (through May).

Quickly see what collaborations have been forged in 2017 in the various therapeutic areas, and drill down for more detail by clicking the hyperlinks to news releases.

This webinar presents an introduction to the key concepts and most common methodologies used to evaluate life sciences businesses and assets. Get an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value.

 

This white paper discusses the role of non-immuno-oncology treatments for cancer in a world where immuno-oncology is playing a greater role...

This white paper is a continuation of the first, entitled "Must-Know Finance Concepts for Life Sciences Valuations." It goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets....

Four panelists from leading global pharmaceutical companies and research organizations discussed theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more. 

There are few people in the world like James Greenwood, BIO CEO, who have as much experience and expertise in successfully connecting biotech companies with large pharma. We recently had the opportunity to sit down with him and pick his brain about the future of biopharma partnering.

Although we have long known about the existence of microbes—the tiny bacteria, fungi and archaea that live all around us, on us, and in us—interest in how the microbiome might impact human therapeutics has become a hot topic in research only recently...

When entering due diligence, it's important to know what information to share and when to share it ensure a timely process. This excel-based due diligence checklist - which is easy to upload to a virtual data room - is designed to make sure you have the information you need for a streamlined due diligence process. 

Gain a high-level overview of the main biopharma partnering deals of 2016, along with links to news articles relating to each deal. Quickly see what collaborations have been forged in the various therapeutic areas.

Due diligence and finance experts from global pharmaceutical companies join legal advisors and consultants to share their expertise in a lively discussion on the issues that arise during due diligence.

 

Learn how Cure SMA leveraged a ShareVault virtual data room to advance one of the very first drug programs focused on finding a cure for Spinal Muscular Atrophy.

Using suppliers is an excellent way to get access to skills and technology that aren’t available internally. However, using suppliers may also create wasted time and effort on the part of the company and the supplier. After both working with suppliers and being a supplier, Maren Nelson has learned...